SAN DIEGO, CA--(Marketwire - Feb 25, 2013) - Lpath, Inc. (
Lpathomab is a first-in-class monoclonal antibody that binds to and neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has been implicated in neuropathic pain, neurotrauma, and various other disorders.
Lpath's vice president and founder, Roger Sabbadini, Ph.D., will present at the Sheraton Crystal City Hotel in Washington, DC on March 7, 2013, at 11:15 a.m. Eastern time. He will discuss a study entitled, "Monoclonal Anti-lysophosphatidic Acid Antibodies Are Neuroprotective after Experimental TBI." The study is part of a collaboration between Lpath and scientists at the University of Melbourne (Alice Pebay, Ph.D. and Peter Crack, Ph.D.), UCLA Brain Injury Research Center (Neil Harris, Ph.D.), and University of Kentucky (Andrew Morris, Ph.D.).
The presentation will demonstrate that: (i) LPA receptors are increased after human brain injury; (ii) LPA levels are upregulated in the cerebrospinal fluid of TBI patients; (iii) Lpathomab administered systemically (single dose post-injury) in mouse models of TBI provides 50+% neuroprotection; and (iv) a single dose of Lpathomab administered two hours post-injury improves neurobehavioral outcomes with functional endpoints.
The data to be presented strongly suggest that LPA dysregulation/upregulation is causal to injury progression following TBI and that interventions to reduce LPA might have a significant impact in mitigating early and late phases of neurotrauma. As such, Lpathomab could satisfy a critical unmet need by limiting the initial neuronal damage and inflammatory processes post-TBI, while subsequently stimulating regenerative processes to optimize long-term functional outcomes after neurotrauma.
Lpath is also pursuing LPA as a novel biomarker for TBI.
According to the conference website (www.tbiconference.com), "Treatment of TBI and especially acute TBI is still a major unmet medical need. Therapies that prove an ability to limit the damage done to the brain and improve clinical outcomes of patients of TBI will have a major impact on the global pharmaceutical market. Although past clinical trials for new therapies have ended in failure, there is indeed renewed interest in this field and with recent initiatives from both the U.S. Congress and Department of Defense to improve treatment options for TBI patients, the time has come for a rethinking of the potential for pharmaceutical management of this condition."
San Diego-based Lpath, Inc., a therapeutic antibody company, is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate monoclonal antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company is developing three drug candidates: iSONEP™ is in a Phase 2 trial for wet AMD; ASONEP™ is in a Phase 2 trial in Renal Cell Carcinoma patients; and Lpathomab is a preclinical drug candidate that holds promise in pain, neurotrauma, and other diseases.